Physician profile
Kirankumar Patel
NPI 1679002083
$373.90
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $26.63 · 2021: $152 · 2022: $196.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $100.15 | 2020-2022 | |
| Daiichi Sankyo INC. | $36.99 | 2021 | |
| Pfizer INC. | $30.85 | 2021 | |
| Sanofi-Aventis U.S. LLC | $27.96 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.94 | 2022 | |
| Lilly USA, LLC | $23.35 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.28 | 2022 | |
| Glaxosmithkline, LLC. | $20.82 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $19.94 | 2022 | |
| Amgen INC. | $19.81 | 2021 | |
| Bausch Health US, LLC | $17.80 | 2022 | |
| Eisai INC. | $16.00 | 2021 | |
| Philips North America LLC | $11.01 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kirankumar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.